









市场行情
/
股票
/
nasdaq-axsm
/

Axsome Therapeutics Inc

AXSM

152.650USD

+5.650+3.84%

收盘 12/19, 16:00（美东）报价延迟15分钟

7.68B总市值

亏损市盈率 TTM



Axsome Therapeutics Inc

152.650

+5.650+3.84%

概览公司财务分析

概览

公司

财务

分析

关于 Axsome Therapeutics Inc 公司

Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.

Axsome Therapeutics Inc简介



公司代码AXSM

公司名称Axsome Therapeutics Inc

上市日期Nov 19, 2015

CEOTabuteau (Herriot)

员工数量683

证券类型Ordinary Share

年结日Nov 19

公司地址One World Trade Center, 29Th Floor

城市NEW YORK

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编10007

电话12123323241

网址https://www.axsome.com/

公司代码AXSM

上市日期Nov 19, 2015

CEOTabuteau (Herriot)

Axsome Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Roger A. Jeffs, Ph.D.

Independent Director

57.51K

-18.97%

Mr. Nick Pizzie, CPA

Chief Financial Officer

42.67K

-1.00%

Mr. Mark E. Saad

Independent Director

10.30K

Dr. Herriot Tabuteau, M.D.

Chairman of the Board, President, Chief Executive Officer, Founder

7.23K

Mr. Hunter Murdock

General Counsel

Mr. Mark L. Jacobson

Chief Operating Officer

-100.00%

Dr. Susan M. (Sue) Mahony, Ph.D.

Independent Director

Dr. Mark Coleman, M.D.

Lead Independent Director

Mr. Ari Maizel

Chief Commercial Officer

名称

名称/职务

职务

持股

持股变动

Dr. Roger A. Jeffs, Ph.D.

Independent Director

57.51K

-18.97%

Mr. Nick Pizzie, CPA

Chief Financial Officer

42.67K

-1.00%

Mr. Mark E. Saad

Independent Director

10.30K

Dr. Herriot Tabuteau, M.D.

Chairman of the Board, President, Chief Executive Officer, Founder

7.23K

Mr. Hunter Murdock

General Counsel

Mr. Mark L. Jacobson

Chief Operating Officer

-100.00%

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2023

FY2023Q4

FY2023Q3

业务USD

名称

营收

占比

Auvelitv

119.64M

80.32%

Sunosi

28.91M

19.41%

Sunosi royality revenue

1.08M

0.73%

Sunosi License revenue

410.00K

0.28%

地区USD

名称

营收

占比

United States

146.45M

98.31%

Outside of the United States

2.51M

1.69%

业务

地区

业务USD

名称

营收

占比

Auvelitv

119.64M

80.32%

Sunosi

28.91M

19.41%

Sunosi royality revenue

1.08M

0.73%

Sunosi License revenue

410.00K

0.28%

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

Antecip Capital, L.L.C.

14.57%

The Vanguard Group, Inc.

8.28%

BlackRock Institutional Trust Company, N.A.

6.16%

Wellington Management Company, LLP

2.65%

RTW Investments L.P.

2.22%

其他

66.13%

持股股东

占比

Antecip Capital, L.L.C.

14.57%

The Vanguard Group, Inc.

8.28%

BlackRock Institutional Trust Company, N.A.

6.16%

Wellington Management Company, LLP

2.65%

RTW Investments L.P.

2.22%

其他

66.13%

股东类型

持股股东

占比

Investment Advisor

36.04%

Investment Advisor/Hedge Fund

21.86%

Corporation

14.57%

Hedge Fund

11.48%

Research Firm

2.23%

Private Equity

1.35%

Individual Investor

1.13%

Pension Fund

1.11%

Sovereign Wealth Fund

0.93%

其他

9.30%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

643

38.50M

85.28%

+81.77K

2025Q3

657

38.45M

87.16%

-264.98K

2025Q2

636

38.74M

85.21%

+673.17K

2025Q1

604

38.08M

85.89%

-4.20M

2024Q4

561

37.78M

89.40%

-1.53M

2024Q3

529

39.25M

94.83%

-2.09M

2024Q2

515

41.51M

92.29%

+1.90M

2024Q1

502

39.61M

93.44%

-4.74M

2023Q4

476

39.34M

91.45%

+441.54K

2023Q3

467

38.94M

87.84%

+1.52M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Antecip Capital, L.L.C.

7.34M

14.72%

Apr 14, 2025

The Vanguard Group, Inc.

3.94M

7.89%

+67.64K

+1.75%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

3.14M

6.3%

+173.97K

+5.86%

Jun 30, 2025

Wellington Management Company, LLP

725.04K

1.45%

+21.77K

+3.09%

Jun 30, 2025

RTW Investments L.P.

1.52M

3.04%

-1.41M

-48.10%

Jun 30, 2025

Nomura Investment Management Business Trust

1.14M

2.28%

+161.49K

+16.54%

Jun 30, 2025

Geode Capital Management, L.L.C.

989.45K

1.98%

+54.60K

+5.84%

Jun 30, 2025

T. Rowe Price Associates, Inc.

575.94K

1.15%

+546.97K

+1888.32%

Jun 30, 2025

Invesco Advisers, Inc.

528.53K

1.06%

-217.30K

-29.14%

Jun 30, 2025

State Street Investment Management (US)

958.50K

1.92%

+52.48K

+5.79%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Neuroscience and Healthcare ETF

4.69%

ALPS Medical Breakthroughs ETF

2.85%

State Street SPDR S&P Pharmaceuticals ETF

2.84%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

2.73%

iShares U.S. Pharmaceuticals ETF

2.09%

Virtus LifeSci Biotech Products ETF

2.03%

ProShares Ultra Nasdaq Biotechnology

0.92%

iShares Health Innovation Active ETF

0.89%

JPMorgan Healthcare Leaders ETF

0.8%

VanEck Pharmaceutical ETF

0.75%

iShares Neuroscience and Healthcare ETF

占比4.69%

ALPS Medical Breakthroughs ETF

占比2.85%

State Street SPDR S&P Pharmaceuticals ETF

占比2.84%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比2.73%

iShares U.S. Pharmaceuticals ETF

占比2.09%

Virtus LifeSci Biotech Products ETF

占比2.03%

ProShares Ultra Nasdaq Biotechnology

占比0.92%

iShares Health Innovation Active ETF

占比0.89%

JPMorgan Healthcare Leaders ETF

占比0.8%

VanEck Pharmaceutical ETF

占比0.75%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Axsome Therapeutics Inc的前五大股东是谁？



Axsome Therapeutics Inc 的前五大股东如下：
Antecip Capital, L.L.C.持有股份：7.34M，占总股份比例：14.72%。
The Vanguard Group, Inc.持有股份：3.94M，占总股份比例：7.89%。
BlackRock Institutional Trust Company, N.A.持有股份：3.14M，占总股份比例：6.30%。
Wellington Management Company, LLP持有股份：725.04K，占总股份比例：1.45%。
RTW Investments L.P.持有股份：1.52M，占总股份比例：3.04%。